Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus

Lupus

Volumn 9, Issue 8, 2000, Pages 566-572

  Ostensen, M ^a   Villiger, P M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cox 1 inhibitors; Cox 2 inhibitors; Practice points; Side effects; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; IBUPROFEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; WARFARIN;

ACUTE KIDNEY FAILURE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASEPTIC MENINGITIS; DRUG HYPERSENSITIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; SKIN TOXICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

EID: 0033777004     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120300678828794     Document Type: Article

References (60)

1. NSAID usage patterns by rheumatologists in the treatment of SLE
2. SLE: A rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up
3. Morbidity and mortality in systemic lupus erythematosus during a 5y period. A multicenter, prospective study of 1,000 patients
4. The management of thrombosis in the antiphospholipid-antibody syndrome
5. Ibuprofen for systemic lupus erythematosus (letter)
6. Long term use of piroxicam in the treatment of systemic lupus erythematosus
7. Toxicity of nonsteroidal anti-inflammatory drugs (NSAIDS) in patients with systemic lupus erythematosus (SLE) (abstract)
8. Cyclooxygenase 1 and 2 in rheumatic disease: Implications for nonsteroidal anti-inflammatory drug therapy
9. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus
10. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus
11. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904
12. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis
13. A review of gastrointestinal manifestations of systemic lupus erythematosus
14. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double-blind comparison
15. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib
16. Localisation of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function
17. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function
18. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
19. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
20. Renal effects of indomethacin in patients with systemic lupus erythematosus
21. Improvement of renal function with selective thromboxane antagonism in lupus nephritis
22. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephrits
23. Renal syndromes associated with nonsteroidal antiinflammatory drugs
24. Minimal change glomerulopathy associated with nonsteroidal anti-inflammatory drugs
25. Refractory nephrotic syndrome in lupus nephritis: Favorable response to indomethacin therapy
26. Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril
27. Cutaneous reactions to nonsteroidal anti-inflammatory drugs
28. Drug allergy in Chinese patients with systemic lupus erythematosus
29. Phototoxic reactions to piroxicam and other nonsteroidal anti-inflammatory agents
30. An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs
31. Role of T cells in drug allergies
32. Mechanisms of adverse reactions in the skin from anti-rheumatic drugs
33. Systemic lupus erythematosus exacerbated by piroxicam
34. Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: Predictive value of anti-ro(SSA) and anti-la(SSB) antibodies and treatment with indomethacin and hydroxychloroquine
35. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor
36. The spectrum of liver disease in systemic lupus erythematosus
37. Sulindac (Clinoril) hepatitis
38. Serious adverse reactions associated with sulindac
39. Effect of aspirin on liver tests in patients with RA or SLE and in normal volunteers
40. Salicylate hepatotoxicity in systemic lupus erythematosus: A common occurrence?
41. Hepatitis secondary to non steroid anti-inflammatory drugs
42. Cyclooxygenase systems in the mammalian brain
43. Lack of association of nonsteroidal anti-inflammatory drug use and cognitive decline in the elderly
44. Central nervous system side effects of nonsteroidal anti-inflammatory drugs
45. Acute central nervous system symptoms caused by ibuprofen in connective tissue disease
46. Sensitization to ibuprofen in systemic lupus erythematosus
47. Ibuprofen may induce meningitis in (NZB x NZW) F mice
48. Infertility may sometimes be associated with NSAID consumption
49. Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs
50. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
51. Treatment of inflammatory rheumatic disorders in pregnancy. What are the safest treatment options?
52. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus
53. Antiphospholipid syndrome in SLE
54. Thrombosis and ischemia in patients with systemic lupus erythematosus treated with celecoxib: A series of two cases
55. Vasodilatators and prostaglandin inhibitors in primary pulmonary hypertension
56. Effects of indomethacin on pulmonary hemodynamics and gas exchange in patients with pulmonary artery hypertension, interference with hydralazine
57. Interactions of non-steroidal anti-inflammatory drugs
58. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis
59. Thrombosis prevention trial: Randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk